KPTI
KARYOPHARM Strikes Forbearance Deal With Lenders and Noteholders
Karyopharm signed a forbearance agreement and limited waiver covering its term loan, both 9.00% convertible note series and its royalty financing.
KPTI
Market-moving news on Karyopharm Therapeutics (NASDAQ: KPTI): filings, earnings, deals and other events, from REDFILED.